Fudan University

Beijing Amsino Medical Co., Ltd.

Junbo Ge

Kun Yang

Xiaoyi Ma

Daxin Zhou

Leilei Cheng

Jingjing Hu

Wenzhi Pan

Aijun Sun

The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt&#x3b2;-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.

Use of Wnt inhibitor Wnt-C59 in preparation of drug for treating SCN5A mutation-induced dilated cardiomyopathy

A valve clamp for treating the cardiac valve regurgitation. The valve clamp includes a first clamp part, a second clamp part, and a connecting part. The first clamp part has the first clamping arms. The second clamp part has a corresponding number of second clamping arms. The first clamping arm and the second clamping arm can clip an object therebetween through the interaction force generated by closing and pushing against each other. Moreover, the valve clamp can also include a closed ring, which is sleeved outside the periphery of the first clamp part and the periphery of the second clamp part, such that the clamping arms can close as needed, and the clamping is tighter. The valve clamp has the advantages of a minimally invasive implantation, a simple manufacture, a low difficulty of operation, good effects, etc.

Valve clamp

An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement.

Arsenic trioxide medical elution scaffold

Growing community of inventors

Shanghai, China

Junbo Ge